Professional Research Publications

Goodman DW. Editorial on Sonuyga-Barke for EBMH. Evidence-Based Mental Health, Brit Med J. May 2013. Question: Are dietary and pharmacological interventions effective for the treatment of attention deficit hyperactivity disorder (ADHD)? Outcomes: Post-treatment change from baseline in total ADHD symptom severity as measured by ADHD-specific symptom scales (eg, the Diagnostic and Statistical Manual of Mental […]

Goodman DW. Ther Clin Risk Manag. 2013;9:121-30. Abstract Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that often persists throughout life. Approximately two-thirds of patients with a childhood diagnosis of ADHD continue to experience clinically significant symptoms into adulthood. Nevertheless, most of these individuals consider themselves “well,” and a vast majority discontinue medication treatment during adolescence. As […]

Mattingly G, Weilser RH, Young J, Adeyi B, Dirks B, Babcock T, Lasser R, Scheckner, B, Goodman, D BioMed Central Psychiatry BMC Psychiatry 2013, 13:39 Background Despite the overall high degree of response to pharmacotherapy, consensus is lacking on how to judge clinical response or define optimal treatment/remission when treating adults with attention-deficit/hyperactivity disorder (ADHD). […]

Article medically reviewed by David W. Goodman M.D. 2012 Experts suggest that attention deficit hyperactivity disorder (ADHD) affects an estimated 8 percent of school-aged children, and about two-thirds of children diagnosed with ADHD continue to show signs of the disorder into adulthood. [button size=’large’ color=’btn-b76lpc214h’ link=’https://www.healthywomen.org/condition/attention-deficit-hyperactivity-disorder’ align=’center’ block=’0′ icon=’FontAwesome/fontawesome-chevron-sign-right||color:ffffff’ shadow=’2′]Read Full Article[/button]

Goodman DW, Surman CB, Scherer P, Salinas G. Primary Psychiatry. February, 2012. Objective Adult attention-deficit/hyperactivity disorder (ADHD) is a common neuropsychiatric disorder, yet only 1 in 10 affected adults receives treatment. The study objective was to assess gaps in knowledge and describe current practice patterns of primary care physicians and psychiatrists in the United States in […]

Lifespan Persistence of ADHD: The Life Transition Model and Its Application. Atilla Turgay, MD; David W. Goodman, MD; Philip Asherson, MRCPsych, PhD; Robert A. Lasser, MD; Thomas F. Babcock, DO; Michael L. Pucci, PhD; and Russell Barkley, PhD, for the ADHD Transition Phase Model Working Group COPYRIGHT 2012 PHYSICIANS POSTGRADUATE PRESS, INC. © COPYRIGHT 2012 […]

Goodman DW medical editor. Consumer Report. 2012

David W. Goodman, MD1 Robert A. Lasser, MD2 Thomas Babcock, DO2 Michael L. Pucci, PhD3 Mary V. Solanto, PhD4. Managing ADHD Across the Lifespan in the Primary Care Setting. © Postgraduate Medicine, Volume 123, Issue 5, September 2011, ISSN – 0032-5481, e-ISSN – 1941-9260 [button size=’large’ color=’btn-b76lpc214h’ link=’https://addadultdev2024.talondigital.com/wp-content/uploads/2013/12/Goodman_DW_et_al_2011_Managing_ADHD_Across_the_Lifespan_in_the_Primary_Care_Setting.pdf’ align=’center’ block=’0′ icon=’FontAwesome/fontawesome-chevron-sign-right||color:ffffff’ shadow=’2′]Read Full Article[/button]

Stephen V. Faraone, Thomas J. Spencer, Scott H. Kollins, Stephen J. Glatt and David Goodman. Dose Response Effects of Lisdexamfetamine Dimesylate Treatment in Adults With ADHD: An Exploratory Study. Journal of Attention Disorders published online April 28, 2011 [button size=’large’ color=’btn-b76lpc214h’ link=’https://addadultdev2024.talondigital.com/wp-content/uploads/2011/04/Faraone_SV_et_al_2011_Dose_Response_Effects_of_LDX_Tx_in_Adults_with_ADHD_An_Explortory_Study.pdf’ align=’center’ block=’0′ icon=’FontAwesome/fontawesome-chevron-sign-right||color:ffffff’ shadow=’2′]Read Full Article[/button]

Weisler R, Adler LA, Kollins SH, Goodman DW, Hamdani M, Dirks B, Childress A. Analysis of Individual Items on the Attention-Deficit/Hyperactivity Disorder Symptom Rating Scale in Children and Adults: Part 1. The Effects of Age and Sex in Pivotal Trials of Lisdexamfetamine Dimesylate. J of Atten Disorders (in press)